UMBRAYA - Trademark Details
Status: 734 - Fifth Extension - Granted
Image for trademark with serial number 88155166
Serial Number
88155166
Word Mark
UMBRAYA
Status
734 - Fifth Extension - Granted
Status Date
2021-11-17
Filing Date
2018-10-15
Mark Drawing
4000 - Standard character mark Typeset
Published for Opposition Date
2019-03-05
Attorney Name
Law Office Assigned Location Code
L40
Employee Name
FATHY, DOMINIC
Statements
Goods and Services
Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonia, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhidrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing pharmaceutical preparations; Pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations and medicines for the treatment of sensory organ disorders; Pharmaceutical preparations and medicines for the treatment of central nervous system disorders; Pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; Pharmaceutical preparations and medicines for the treatment of circulatory system disorders; Pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2018-10-25
Primary Code
005
Current Trademark Owners
Party Type
20 - Owner at Publication
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Party Type
20 - Owner at Publication
Address
Please log in with your Justia account to see this address.
Party Type
10 - Original Applicant
Address
Please log in with your Justia account to see this address.
Correspondences
Name
Matthew O. Brady
Address
Please log in with your Justia account to see this address.
Trademark Events
Event DateEvent Description
2018-10-18NEW APPLICATION ENTERED IN TRAM
2018-10-25NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
2019-01-24ASSIGNED TO EXAMINER
2019-01-25APPROVED FOR PUB - PRINCIPAL REGISTER
2019-02-13NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
2019-03-05PUBLISHED FOR OPPOSITION
2019-03-05OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
2019-04-30NOA E-MAILED - SOU REQUIRED FROM APPLICANT
2019-10-28TEAS EXTENSION RECEIVED
2019-10-28EXTENSION 1 FILED
2019-10-28EXTENSION 1 GRANTED
2019-10-28TEAS EXTENSION RECEIVED
2019-10-30NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2019-10-31CASE ASSIGNED TO INTENT TO USE PARALEGAL
2019-10-31EARLY EXTENSION OF USE REFUSED
2020-04-08TEAS EXTENSION RECEIVED
2020-04-08EXTENSION 2 FILED
2020-04-08EXTENSION 2 GRANTED
2020-04-10NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2020-10-02TEAS EXTENSION RECEIVED
2020-10-02EXTENSION 3 FILED
2020-10-02EXTENSION 3 GRANTED
2020-10-06NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2021-03-15TEAS EXTENSION RECEIVED
2021-03-15EXTENSION 4 FILED
2021-03-15EXTENSION 4 GRANTED
2021-03-17NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
2021-10-20TEAS EXTENSION RECEIVED
2021-11-16CASE ASSIGNED TO INTENT TO USE PARALEGAL
2021-10-20EXTENSION 5 FILED
2021-11-17EXTENSION 5 GRANTED
2021-11-18NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED